Dexcom

What Dexcom does

Dexcom (NASDAQ: DXCM), founded in 1999 and headquartered in San Diego, develops, manufactures, and distributes continuous glucose monitoring (CGM) systems used by people with diabetes and prediabetes. Its portfolio centers on two platforms: the prescription Dexcom G7 / G7 15-Day CGM systems for Type 1, intensive-insulin Type 2, and gestational diabetes — providing real-time interstitial glucose readings every 5 minutes, predictive low alerts 20 minutes ahead, and direct-to-Apple-Watch connectivity — and the over-the-counter Stelo Glucose Biosensor for adults and (as of June 2026) children ages 2+ who are not on insulin, including Type 2 non-insulin users and prediabetics. Supporting software includes the Dexcom Clarity clinical analytics platform, the Dexcom Follow remote-monitoring app, and a redesigned Stelo app with AI coaching launched mid-2026. The next-generation G8 platform (50% smaller than G7, at least 10% lower manufacturing cost, additional physiological sensing) was announced at the May 2026 Investor Day with FDA submission planned for 2027.

Revenue is generated primarily through recurring sales of disposable CGM sensors that patients replace every 10–15 days, sold through two channels: (1) U.S. insurance-reimbursed pharmacy (PBM) and durable medical equipment (DME) channels — where most covered patients pay $20 or less per month and Medicare patients generally pay $0 — and (2) the direct-to-consumer Stelo.com storefront for pay-as-you-go and subscription OTC purchases. Dexcom serves 3.5M+ patients globally, operates in 40+ countries through wholly-owned regional entities, and sells to the full diabetes and metabolic-health value chain including endocrinologists, primary care physicians, payers (CVS/caremark, Express Scripts, OptumRx, Prime Therapeutics), insulin pump and pen partners, wellness platforms (Hims & Hers, Signos, Oura), and recently expanded into AI-driven nutrition coaching through the Nutrisense acquisition.

Name

Dexcom

Legal name

Dexcom, Inc.

Website

https://dexcom.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Dexcom (NASDAQ: DXCM) is a San Diego-based medical device company that develops continuous glucose monitoring (CGM) systems — including prescription Dexcom G7 and OTC Stelo — for people with Type 1, Type 2, gestational diabetes and prediabetes, serving 3.5M+ patients globally.

Ownership category

akta.pro rank

Product category

Continuous Glucose Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)

akta.pro secondary industries

Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)

Keywords

• Continuous glucose monitoring
• Diabetes medical devices
• Glucose biosensor systems
• CGM sensor manufacturing
• Metabolic health monitoring

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices17 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. CGM Sensor and Device Sales (Recurring Disposable): Dexcom generates the majority of revenue from recurring sales of disposable CGM sensors that patients replace every 10-15 days depending on the product. Sensors are sold through pharmacy (retail) and DME (durable medical equipment) channels with insurance reimbursement. The subscription-like recurring revenue model is driven by continuous patient usage requiring regular sensor replacements.
2. OTC Stelo Glucose Biosensor (Direct-to-Consumer): Stelo is sold directly to consumers without prescription through Stelo.com with pay-as-you-go and subscription options. This OTC channel provides a new non-insurance revenue stream targeting the broader non-insulin diabetes and prediabetes population.
3. Dexcom Clarity Software/Analytics: Cloud-based data management platform providing retrospective glucose analysis, pattern reports, and clinical decision support for patients and healthcare providers.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Dexcom develops, manufactures, and sells continuous glucose monitoring (CGM) systems that measure interstitial fluid glucose levels and transmit readings in real time to smartphones or receivers. Its portfolio includes prescription CGM devices (Dexcom G7 and G7 15 Day) for people with Type 1, Type 2 on insulin, and gestational diabetes, and the over-the-counter Stelo Glucose Biosensor for adults 18+ not on insulin, including those with prediabetes or Type 2 diabetes on oral medications. Supporting offerings include the cloud-based Dexcom Clarity analytics platform, the Dexcom Follow caregiver app, and the AI-powered Stelo mobile app with pattern recognition and personalized coaching.

Product overview

Dexcom is a medical device company specializing in continuous glucose monitoring (CGM) systems for diabetes management. The portfolio consists of two main CGM platforms: the prescription Dexcom G7/G7 15 Day/G8 systems for people with Type 1, Type 2, or gestational diabetes, and the over-the-counter Stelo Glucose Biosensor for adults not using insulin including those with prediabetes or Type 2 diabetes on oral medications. Supporting software includes Dexcom Clarity (clinical analytics), Dexcom Follow (remote monitoring for caregivers), and the AI-powered Stelo app with coaching features. Dexcom also recently acquired Nutrisense for nutrition guidance and launched Dexcom Flex internationally for Type 2 non-intensive insulin users. The G8 next-generation platform was announced in 2026 with FDA submission planned for 2027.

Differentiator

Problem solved

Functional benefit

Brands

• Dexcom G7: Continuous glucose monitoring system designed for all people living with T1, T2, or gestational diabetes, delivering real-time glucose readings to phone or receiver
• Stelo
• Dexcom Clarity
• Dexcom ONE
• Dexcom Share
• Dexcom Follow
• Dexcom Flex
• Dexcom G8

Products and services

• Dexcom G7 CGM System

Quantifiable outcome

• 1.6% average A1C reduction in type 2 non-insulin patients using Dexcom G7 (vs. 0.7% for routine care) over 26 weeks — CONNECT trial
• +6 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration12 records

AI capability9 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core, minor and flagship.

• NutrisensecoreStrategic or Co-development Partner · 5 June 2026Dexcom entered into an agreement to acquire Nutrisense, a wellness app company using data from continuous glucose monitors to provide personalized nutrition guidance and behavior-change support. The acquisition aims to position Dexcom as a full metabolic-health ecosystem by combining real-time glucose monitoring with registered dietitians and AI-powered nutrition coaching. Transaction expected to close in the coming weeks pending regulatory approvals.
• Hims & Hers HealthminorGTM or Marketing Partner · 28 May 2026Dexcom Stelo became available as a subscriber benefit through Hims & Hers' wellness benefits program, offering subscribers discounts and metabolic monitoring integration. The expansion offers subscribers metabolic monitoring partner access alongside fitness, nutrition, and women's health partners as part of the GLP-1 treatment program ecosystem.
• SignoscoreStrategic or Co-development Partner · 27 May 2026Dexcom invested $20 million in Signos (alongside GV/Google Ventures and Blue Cross Blue Shield of Alabama's 450 Ventures). Signos, an FDA-cleared AI-powered glucose monitoring platform for weight management, became available for purchase through Dexcom's direct-to-consumer Stelo.com platform. The partnership extends Dexcom's reach into the GLP-1 weight loss and wellness market, with projections indicating the global CGM market could surpass $15 billion by 2028.
• OuraminorStrategic or Co-development Partner · 1 May 2025Oura ring integrates glucose insights from Dexcom's Stelo CGM alongside its sleep, activity, and recovery metrics using AI-generated summaries. This partnership positions AI interpretation layers as the new competitive battleground in consumer health technology, with glucose data becoming a test case for responsible AI health assistance. Oura has sold 5.5 million rings and filed confidentially for IPO.
• 90+ Connected Insulin Pump, Pen, and Health App PartnerscoreTechnology or IntegrationDexcom is the most connected CGM ecosystem with 90+ integrations including insulin pumps (Insulet Omnipod, Tandem Diabetes Care), connected insulin pens, and digital health apps. The company's CONNECT clinical data supports expanded AID (Automated Insulin Delivery) system integrations.
• ApplecoreTechnology or IntegrationDexcom G7 offers direct-to-watch connectivity, sending glucose readings and alerts directly to Apple Watch without requiring a nearby iPhone. This is the most independent Apple Watch experience among CGM systems. Dexcom is compatible with Apple HealthKit for health data integration.
• GLP-1 Medication Manufacturers (Novo Nordisk, Eli Lilly)coreStrategic or Co-development PartnerDexcom's CONNECT trial data shows enhanced benefits when G7 is used alongside GLP-1 medications. The company positions CGM as complementary to GLP-1 therapies for type 2 diabetes, with rising GLP-1 adoption expanding the addressable market for glucose monitoring.
• Prime TherapeuticsflagshipChannel Partner/ Reseller/ DistributorPrime Therapeutics, a pharmacy benefit manager, signed a coverage agreement with Dexcom beginning summer 2026, extending commercial coverage to over 7 million type 2 non-insulin lives. This follows coverage expansions across the three largest U.S. PBMs (CVS/caremark, Express Scripts, OptumRx).
• CVS/caremark, Express Scripts, OptumRx (Three Largest U.S. PBMs)flagshipChannel Partner/ Reseller/ DistributorInsurance reimbursement expanded to cover nearly 6 million type 2 non-insulin diabetes patients across the three largest U.S. pharmacy benefit managers. This coverage expansion is a major catalyst for Dexcom's addressable market growth, with Medicare T2NIT coverage decision expected by mid-2027.

Scale indicators12 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Abbott: Abbott's Diabetes Care division sells the FreeStyle Libre family of CGMs, Dexcom's primary direct competitor. Together they dominate the global CGM market, with Abbott holding ~28% share versus Dexcom's ~24%, and is the most directly comparable peer across product, target customer, and business model.
• Medtronic: Medtronic manufactures the Guardian CGM system integrated with its MiniMed insulin pumps in automated insulin delivery systems. Comparable to Dexcom as a CGM manufacturer targeting type 1 and intensive-insulin patients, with overlapping integrated pump+CGM offerings.
• Insulet Corporation: Insulet makes the Omnipod insulin pump, one of Dexcom's largest integration partners for automated insulin delivery. Comparable as a connected diabetes device company, though its core product is an insulin pump rather than a CGM sensor.
• Tandem Diabetes Care: Tandem Diabetes Care manufactures the t:slim X2 insulin pump, tightly integrated with Dexcom CGM for closed-loop AID systems (Control-IQ). Comparable as a connected diabetes device company targeting type 1 patients with overlapping customer base and ecosystem partnership with Dexcom.

Emerging players

• Senseonics Holdings: Senseonics makes the Eversense implantable CGM, an alternative long-duration (180-day) CGM option. It is comparable as a CGM competitor in the diabetes space but with a fundamentally different implantable form factor, making it a niche/emerging player rather than a broad direct peer.
• Signos: Signos is an FDA-cleared AI-powered CGM-based weight management platform that received a $20M investment from Dexcom Ventures and is now distributed through Stelo.com. Comparable as an emerging player in the consumer CGM/wellness space where Dexcom's Stelo competes and partners.

Broad incumbents

• Roche Diabetes Care: Roche Diabetes Care offers Accu-Chek blood glucose meters and is exploring CGM/digital diabetes solutions as part of a broader diabetes portfolio. Comparable as a large diabetes-care incumbent, though it is not currently a direct CGM sensor competitor.
• LifeScan:

Others

• Eli Lilly: Eli Lilly is a leading GLP-1 receptor agonist manufacturer (Mounjaro, Zepbound) and is a key complementary therapy partner for Dexcom. The CONNECT trial shows enhanced CGM+GLP-1 outcomes, making Lilly an adjacent ecosystem player and potential partner/customer rather than a direct competitor.
• Novo Nordisk: Novo Nordisk manufactures Ozempic, Wegovy, and other GLP-1 therapies that complement CGM use in type 2 diabetes and weight management. Relevant as an adjacent metabolic-health ecosystem player and Dexcom partner in the GLP-1+CGM combination story.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dexcom
• Xx.com/dexcom
• Facebookfacebook.com/dexcom

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries20 records

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dexcom